2-(2-(pyridin-2-yldisulfanyl)phenyl)acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(2-(pyridin-2-yldisulfanyl)phenyl)acetic acid
• 英文别名: 2-[2-(Pyridin-2-yldisulfanyl)phenyl]acetic acid；2-[2-(pyridin-2-yldisulfanyl)phenyl]acetic acid
• 化学式: C₁₃H₁₁NO₂S₂
• 分子量: 277.368
• InChiKey: RTKVMJYVPWIJPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-(pyridin-2-yldisulfanyl)phenyl)acetic acid 、 紫杉醇 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以68%的产率得到paclitaxel-2-(2-(pyridin-2-yldisulfanyl)phenyl)acetate
  参考文献：
  名称：

  Cancer cell surface induced peptide folding allows intracellular translocation of drug

  摘要：

  Many lead molecules identified in drug discovery campaigns are eliminated from consideration due to poor solubility and low cell permeability. These orphaned molecules could have clinical value if solubilized and delivered properly. SVS-1 is a de novo designed peptide that preferentially folds at the surface of tumor cells, adopting a beta-hairpin conformation that rapidly translocates into the cytoplasm, and ultimately nucleus, of cells. SVS-1 is stable in serum and small molecules attached to the peptide are effectively delivered to cancer cells via mechanisms involving physical translocation and, to a lesser extent, clathrin-dependent endocytosis. For example, ligating the model hydrophobic drug Paclitaxel (PTX) to SVS-1 improved its aqueous solubility by similar to 1000-fold and successfully delivered and released PTX to cancer cells in vitro and tumors in vivo without toxic adjuvants. These results suggest that SVS-1 can serve as a simple, effective delivery platform for molecules with poor solubility and permeability. Published by Elsevier B.V.

  DOI：

  10.1016/j.jconrel.2015.05.267
• 作为产物：
  描述：

  苯并[b]噻吩-2(3H)-酮 在 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 22.17h， 生成 2-(2-(pyridin-2-yldisulfanyl)phenyl)acetic acid
  参考文献：
  名称：

  一种反应型巯基化合物探针及其制备方法

  摘要：

  本发明公开了一种反应型巯基化合物探针及其制备方法，基于硫醇参与的二硫键断裂反应，传感分子释放出罗丹明染料分子单体，荧光强度显著性增强并伴随明显的颜色变化，选取的干扰离等对检测效果几乎无影响，因而实现了对巯基化合物的特异性识别响应，检测限达0.124μM。

  公开号：

  CN107141303B

文献信息

• 一种反应型巯基化合物探针及其制备方法
  申请人：许昌学院

  公开号：CN107141303B

  公开（公告）日：2019-03-15

  本发明公开了一种反应型巯基化合物探针及其制备方法，基于硫醇参与的二硫键断裂反应，传感分子释放出罗丹明染料分子单体，荧光强度显著性增强并伴随明显的颜色变化，选取的干扰离等对检测效果几乎无影响，因而实现了对巯基化合物的特异性识别响应，检测限达0.124μM。
• SYNTHETIC NANOCARRIERS WITH REACTIVE GROUPS THAT RELEASE BIOLOGICALLY ACTIVE AGENTS
  申请人：Zepp Charles

  公开号：US20120171229A1

  公开（公告）日：2012-07-05

  This invention relates to compositions, and related compounds and methods, of conjugates of synthetic nanocarriers, or components thereof, and biologically active agents, such as immunomodulatory agents, antigens, anticancer agents or antiviral agents. The biologically active agents are released from the synthetic nanocarriers in the presence of a reducing agent or by reaction with a thiol.

  这项发明涉及合成纳米载体的结合物、相关化合物和方法，其中合成纳米载体或其组分与生物活性剂（如免疫调节剂、抗原、抗癌剂或抗病毒剂）的结合物。生物活性剂在还原剂存在或与巯基反应的情况下从合成纳米载体中释放。
• [EN] SYNTHETIC NANOCARRIERS WITH REACTIVE GROUPS THAT RELEASE BIOLOGICALLY ACTIVE AGENTS<br/>[FR] NANO-VECTEURS SYNTHÉTIQUES AYANT DES GROUPES RÉACTIFS QUI LIBÈRENT DES AGENTS BIOLOGIQUEMENT ACTIFS
  申请人：SELECTA BIOSCIENCES INC

  公开号：WO2012092552A1

  公开（公告）日：2012-07-05

  This invention relates to compositions, and related compounds and methods, of conjugates of synthetic nanocarriers, or components thereof, and biologically active agents, such as immunomodulatory agents, antigens, anticancer agents or antiviral agents. The biologically active agents are released from the synthetic nanocarriers in the presence of a reducing agent or by reaction with a thiol.
• [EN] PEPTIDE DRUG CONJUGATES<br/>[FR] CONJUGUÉS PEPTIDES-MÉDICAMENTS
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2017136769A1

  公开（公告）日：2017-08-10

  Embodiments provide protein-drug conjugates for treatment of cancer. Protein-drug conjugates may include protein-drug conjugates of Formula I: Ctx-L-Cp (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: Ctx is chlorotoxin or a chlorotoxin analog; Cp is a cryptophycin amide, and L is a linker wherein the linker is bound to Ctx at an X2 moiety of the linker and at one of a lysine residue and the N-terminus of the chlorotoxin or chlorotoxin analog.
• Cancer cell surface induced peptide folding allows intracellular translocation of drug
  作者：Scott H. Medina、Joel P. Schneider

  DOI：10.1016/j.jconrel.2015.05.267

  日期：2015.7

  Many lead molecules identified in drug discovery campaigns are eliminated from consideration due to poor solubility and low cell permeability. These orphaned molecules could have clinical value if solubilized and delivered properly. SVS-1 is a de novo designed peptide that preferentially folds at the surface of tumor cells, adopting a beta-hairpin conformation that rapidly translocates into the cytoplasm, and ultimately nucleus, of cells. SVS-1 is stable in serum and small molecules attached to the peptide are effectively delivered to cancer cells via mechanisms involving physical translocation and, to a lesser extent, clathrin-dependent endocytosis. For example, ligating the model hydrophobic drug Paclitaxel (PTX) to SVS-1 improved its aqueous solubility by similar to 1000-fold and successfully delivered and released PTX to cancer cells in vitro and tumors in vivo without toxic adjuvants. These results suggest that SVS-1 can serve as a simple, effective delivery platform for molecules with poor solubility and permeability. Published by Elsevier B.V.